Loading...
Loading...
ALEC| Name | Value |
|---|---|
| Revenues | 15.1M |
| Cost of Revenue | 2.3M |
| Gross Profit | 12.8M |
| Operating Expense | 58.4M |
| Operating I/L | -45.6M |
| Other Income/Expense | 7.0M |
| Interest Income | 0.0M |
| Pretax | -38.6M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -38.7M |
Alector, Inc. is a clinical stage biopharmaceutical company specializing in developing therapies for neurodegenerative diseases. Their product portfolio includes AL001, a humanized recombinant monoclonal antibody in Phase III clinical trial for frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases. They also offer AL101 in Phase I clinical trial for neurodegenerative diseases. Additionally, the company has products in development stages, such as AL002 and AL003 for Alzheimer's disease, and AL044 targeting MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. generates revenue through the research, development, and commercialization of monoclonal antibodies for the treatment of neurodegenerative diseases.
